Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kodiak SciencesMEX:KOD 27 PB Ratio is 23.03 as of Jul. 14, 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Kodiak Sciences ranks worse than 94.3% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), Kodiak Sciences's share price is MXN749.00. Kodiak Sciences's Book Value per Share for the quarter that ended in Mar. 2026 was MXN32.52. Hence, Kodiak Sciences's PB Ratio of today is 23.03.
The historical rank and industry rank for Kodiak Sciences's PB Ratio or its related term are showing as below:
MEX:KOD'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 22.78
Current: 22.78
During the past 10 years, Kodiak Sciences's highest PB Ratio was 22.78. The lowest was 0.00. And the median was 0.00.
MEX:KOD's PB Ratio is ranked worse than 94.3% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs MEX:KOD: 22.78
During the past 12 months, Kodiak Sciences's average Book Value Per Share Growth Rate was -10.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Kodiak Sciences was 75.70% per year. The lowest was -39.40% per year. And the median was -32.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kodiak Sciences PB Ratio Related Terms
Kodiak Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Kodiak Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kodiak Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Kodiak Sciences's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kodiak Sciences (MEX:KOD) has a PB Ratio of 23.03 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #1158 out of 1228 companies in the Biotechnology industry, placing it in the top 94.3%.
Is Kodiak Sciences' PB Ratio too high?
Kodiak Sciences' current PB Ratio is 23.03. The Biotechnology industry median PB Ratio is 2.89. Kodiak Sciences' value of 23.03 is 698.3% above this industry median. Based on the distribution chart, Kodiak Sciences ranks #1158 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' PB Ratio compare to ABCL and AGIO?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #1158 out of 1228 companies for PB Ratio. This places Kodiak Sciences in the lower half of its industry. The industry median PB Ratio is 2.89. Kodiak Sciences' value of 23.03 is 698.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kodiak Sciences's current PB Ratio of 23.03 is 698.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kodiak Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kodiak Sciences's current PB Ratio is 23.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current PB Ratio of 23.03. The current PB Ratio is 23.03 and 698.3% above the Biotechnology industry median of 2.89. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current PB Ratio is 23.03 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score
Get the complete analysis for MEX:KOD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KOD has been successfully added to your 
